Skip to main content

Advertisement

SpringerLink
Log in

Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins

  • Invited Commentary
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587–595.

    Article  PubMed  CAS  Google Scholar 

  2. Denton CP, Black CM: Targeted therapy comes of age in scleroderma. Trends Immunol 2005, 26:596–602.

    Article  PubMed  CAS  Google Scholar 

  3. Murasawa S, Asahara T: Endothelial progenitor cells for vasculogenesis, Physiology (Bethesda) 2005, 20:36–42.

    CAS  Google Scholar 

  4. Clancy RM: Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells? Arthritis Rheum 2006, 54:1730–1732.

    Article  PubMed  Google Scholar 

  5. Simons M: Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 2005, 46:835–837.

    Article  PubMed  Google Scholar 

  6. Kuwana M, Okazaki Y, Yasuoka H, et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603–610.

    Article  PubMed  CAS  Google Scholar 

  7. Distler O, Del Rosso A, Giacomelli R, et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.

    Article  PubMed  Google Scholar 

  8. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 2003, 24:225–248.

    Article  PubMed  CAS  Google Scholar 

  9. Llevadot J, Murasawa S, Kureishi Y, et al.: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001, 108:399–405.

    Article  PubMed  CAS  Google Scholar 

  10. Furukawa S, Yasuda S, Amengual O, et al.: Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006, 65:1118–1120.

    Article  PubMed  CAS  Google Scholar 

  11. Kuwana M, Kaburaki J, Okazaki Y, et al.: Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006, 54:1946–1951.

    Article  PubMed  CAS  Google Scholar 

  12. Derk CT, Jimenez SA: Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 2006, 5:25–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Northwestern University Feinberg School of Medicine, McGaw Pavilion, 240 East Huron Street, Chicago, IL, 60611-2909, USA

    John Varga MD

Authors
  1. Monique Hinchcliff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Varga MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Varga MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hinchcliff, M., Varga, J. Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins. Curr Rheumatol Rep 9, 1–3 (2007). https://doi.org/10.1007/s11926-007-0014-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0014-1

Keywords

Search

Navigation